We have located links that may give you full text access.
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Dopamine D2/3 receptor availability and amphetamine-induced dopamine release in obesity.
Journal of Psychopharmacology 2014 September
INTRODUCTION: The neurotransmitter dopamine is important in the regulation of food intake. It is hypothesised that obese people experience less reward from food due to lower striatal dopamine release, which consequently leads to overeating. This study is the first to assess whether obese subjects have blunted striatal dopamine release.
METHOD: We measured striatal dopamine D2/3 receptor (DRD2/3) availability and amphetamine-induced striatal dopamine release in 15 obese and 15 age-matched, normal-weight women using [(123)I]iodobenzamide single photon emission computed tomography (SPECT) imaging. In addition, correlations with food craving were examined.
RESULTS: Baseline striatal DRD2/3 availability was lower in obese subjects (0.91 ± 0.16) compared to controls (1.09 ± 0.16; p = 0.006). Amphetamine-induced dopamine release was significant in controls (7.5% ± 9.2; p = 0.007) and not in obese subjects (1.2% ± 17.7; p = 0.802), although the difference in release between groups (d=0.45) was not significant. Dopamine release positively correlated with the trait food craving in obese subjects.
CONCLUSION: This study replicates previous findings of lower striatal DRD2/3 availability in obesity and provides preliminary data that obesity is associated with blunted dopamine release. The positive correlation between dopamine release and food craving in obesity may seem contradictory with the latter finding but is presumably related to heterogeneity within the obese subjects.
METHOD: We measured striatal dopamine D2/3 receptor (DRD2/3) availability and amphetamine-induced striatal dopamine release in 15 obese and 15 age-matched, normal-weight women using [(123)I]iodobenzamide single photon emission computed tomography (SPECT) imaging. In addition, correlations with food craving were examined.
RESULTS: Baseline striatal DRD2/3 availability was lower in obese subjects (0.91 ± 0.16) compared to controls (1.09 ± 0.16; p = 0.006). Amphetamine-induced dopamine release was significant in controls (7.5% ± 9.2; p = 0.007) and not in obese subjects (1.2% ± 17.7; p = 0.802), although the difference in release between groups (d=0.45) was not significant. Dopamine release positively correlated with the trait food craving in obese subjects.
CONCLUSION: This study replicates previous findings of lower striatal DRD2/3 availability in obesity and provides preliminary data that obesity is associated with blunted dopamine release. The positive correlation between dopamine release and food craving in obesity may seem contradictory with the latter finding but is presumably related to heterogeneity within the obese subjects.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app